drugset / Trial / NCT00002424

A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine

NCT00002424

Phase 2 Suspended 186 enrolled Merck Sharp & Dohme LLC
Double-blindTreatment

Summary

This study will see how safe and effective against HIV the drugs L-756423 plus indinavir (IDV) are compared to just IDV when taken with stavudine (d4T) and lamivudine (3TC). The study will also see whether taking 1 large dose of L-756423/IDV once a day is as safe and effective as taking 2 smaller doses twice a day.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject INDINAVIR ANHYDROUS Other / unclassified 400 mg
Subject INDINAVIR ANHYDROUS Other / unclassified 800 mg
Subject L-756423 Small molecule 800 mg
Subject L-756423 Small molecule 1600 mg
Background Lamivudine Other / unclassified
Background Stavudine Other / unclassified